UCB

UCB, IBM collaborate to personalize care for epilepsy patients

Wednesday, May 22, 2013 11:05 AM

UCB, a Belgium-based global biopharmaceutical company focused on diseases of the immune system and central nervous system, and IBM have completed the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessing the transformative power of cognitive computing capabilities, such as IBM Watson, for epilepsy care.

More... »

UCB and ConfometRx announce new R&D partnership

Friday, February 22, 2013 12:13 PM

UCB, a Belgium-based biopharmaceutical company, has sealed a research agreement with Santa Clara, Calif.-based ConfometRx to enable the discovery of novel medicines addressing unmet medical needs in neuroscience.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Aesica wins European Outsourcing award for UCB acquisition strategy

Thursday, November 1, 2012 10:53 AM

Aesica, a global contract manufacturing organization, has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites—at Monheim and Zwickau, Germany, and Pianezza in, Italy, in 2011.

More... »

UCB expands biotechnology base in Belgium

Monday, September 17, 2012 02:02 PM

In line with its strategy, and in preparation for the growing demand for biological medicines, UCB, a biopharma focused on the central nervous system and immune system, has opened its new pilot biotechnology plant at its Braine-L’Alleud site in Belgium.

More... »

UCB expands in Brazil

Thursday, May 31, 2012 11:51 AM

UCB, a global biopharmaceutical company focused on severe diseases, has signed an agreement to acquire 51% of Meizler Biopharma, a privately-owned Brazilian pharmaceutical company.

More... »

invivodata consults on ClinRO instrument for UCB

Friday, May 11, 2012 12:19 PM

Pittsburgh, Penn.-based invivodata, a fully-integrated clinical outcomes assessments company, has been chosen to deliver regulatory consulting services for a phase III trial that UCB is conducting in the development of a unique biopharmaceutical product to treat Rheumatoid Arthritis (RA).

More... »

UCB touts positive phase III Cimzia results

Monday, April 16, 2012 03:58 PM

UCB reported positive top-line results from a phase III study designed to evaluate the efficacy and safety of Cimzia (certolizumab pegol) in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS).

More... »

UCB, Amgen begin phase III postmenopausal osteoporosis program

Friday, April 6, 2012 03:47 PM

UCB, a global biopharmaceutical based in Brussels, Belgium, and biotech Amgen have initiated their sclerostin antibody (CDP7851/AMG785) phase III clinical trial program for the treatment of postmenopausal osteoporosis.

More... »

UCB begins C-EARLY study for rheumatoid arthiritis

Monday, February 27, 2012 03:59 AM

Brussels-based UCB has initiated C-EARLY, a phase III study to evaluate the efficacy and safety of Cimzia (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with rheumatoid arthritis (RA) not previously treated with disease-modifying antirheumatic drugs (DMARDs).

More... »